https://orcid.org/0000-0003-2402-2717
References
- Means RT. Pure red cell aplasia. Blood. 2016;128:2504–2509. doi:https://doi.org/10.1182/blood-2016-05-717140.
- Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–2405. doi:https://doi.org/10.1182/blood-2016-03-643544.
- Cazzola M. Myelodysplastic syndromes. N Engl J Med. 2020;383:1358–1374. doi:https://doi.org/10.1056/NEJMra1904794.
- Charles RJ, Sabo KM, Kidd PG, et al. The pathophysiology of pure red cell aplasia: implications for therapy. Blood. 1996;87:4831–4838.
- Wang SA, Yue G, Hutchinson L, et al. Myelodysplastic syndrome with pure red cell aplasia shows characteristic clinicopathological features and clonal T-cell expansion. Br J Haematol. 2007;138:271–275. doi:https://doi.org/10.1111/j.1365-2141.2007.06648.x.
- Williamson PJ, Oscier DG, Bell AJ, et al. Red cell aplasia in myelodysplastic syndrome. J Clin Pathol. 1991;44:431–432. doi:https://doi.org/10.1136/jcp.44.5.431.
- Park S, Merlat A, Guesnu M, et al. Pure red cell aplasia associated with myelodysplastic syndromes. Leukemia. 2000;14:1709–1710. doi:https://doi.org/10.1038/sj.leu.2401833.
- Greenberg PL, Sun Z, Miller KB, et al. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the eastern cooperative oncology group (E1996). Blood. 2009;114:2393–2400. doi:https://doi.org/10.1182/blood-2009-03-211797.
- Cerchione C, Catalano L, Cerciello G, et al. Role of lenalidomide in the management of myelodysplastic syndromes with del(5q) associated with pure red cell aplasia (PRCA). Ann Hematol. 2015;94:531–534. doi:https://doi.org/10.1007/s00277-014-2192-z.
- Kelaidi C, Park S, Brechignac S, et al. Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide. Leuk Res. 2008;32:1049–1053. doi:https://doi.org/10.1016/j.leukres.2007.11.037.
- Jiang H, Zhang H, Wang Y, et al. Sirolimus for the treatment of multi-resistant pure red cell aplasia. Br J Haematol. 2019;184:1055–1058. doi:https://doi.org/10.1111/bjh.15245.